This week, the ratings of four Biotechnology stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Momenta Pharmaceuticals (NASDAQ:MNTA) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Momenta Pharmaceuticals is a biotechnology company. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Momentum, Earnings Revisions, and Sales Growth, MNTA also gets F’s. For a full analysis of MNTA stock, visit Portfolio Grader.
The rating of Vical Inc. (NASDAQ:VICL) declines this week from a C to a D. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The trailing PE Ratio for the stock is 89.3. For more information, get Portfolio Grader’s complete analysis of VICL stock.
This week, Trius Therapeutics (NASDAQ:TSRX) drops from a C to a D rating. Trius Therapeutics is a biopharmaceutical company. The stock also gets an F in Equity. The stock price has dropped 6.9% over the past month, worse than 3.9% increase the Nasdaq has seen over the same period of time. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock.
PROLOR Biotech (AMEX:PBTH) gets weaker ratings this week as last week’s C drops to a D. PROLOR Biotech offers treatment by using naturally occurring amino acid sequence to slow the removal of therapeutic proteins from the body without increasing toxicity or altering the overall biological activity. The stock also rates an F in Equity. Shares of the stock are changing hands at twice the rate they were a week ago. For more information, get Portfolio Grader’s complete analysis of PBTH stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.